The GPD2 Knockout A-549 Polyclonal Cells product is a polyclonal population of the A-549 human lung adenocarcinoma cell line in which CRISPR/Cas9 has been employed to disrupt the GPD2 gene, generating a heterogeneous loss-of-function model. This polyclonal format preserves a range of genetic alterations across the cell pool, avoiding the artifacts and selection pressures associated with monoclonal isolation, and better mimics the genomic diversity observed in tumor cell populations.
The parental A-549 cells were originally established from an explanted lung tumor of a 58-year-old Caucasian male and are characterized as adherent, hypotriploid epithelial cells. These cells serve as a well-established model of alveolar basal epithelial function, including surfactant production and ion transport, and are routinely utilized in cancer biology, toxicology screening, and metabolic studies. Their robust growth and well-documented signaling make them suitable for interrogating mitochondrial enzymes.
GPD2 encodes mitochondrial glycerol-3-phosphate dehydrogenase, a critical enzyme of the glycerol phosphate shuttle that catalyzes the FAD-dependent oxidation of glycerol-3-phosphate to dihydroxyacetone phosphate (DHAP). Electrons from this reaction are transferred to the FAD cofactor and then, via physical interaction with mitochondrial complex II (succinate dehydrogenase subunits SDHA, SDHB, SDHC, SDHD), to the ubiquinone pool. This mechanism couples the re-oxidation of cytosolic NADH??produced during glycolysis??to the electron transport chain, thereby supporting ATP synthesis and contributing to mitochondrial ROS generation. GPD2 expression and activity are transcriptionally regulated by upstream factors including cAMP, thyroid hormones (T3), and the coactivator PGC-1?? (PPARGC1A), as well as by PPARs and insulin. The glycerol phosphate shuttle is completed by the cytosolic enzyme GPD1, which reduces DHAP back to glycerol-3-phosphate using NADH, thus linking carbohydrate and lipid metabolism to oxidative phosphorylation and gluconeogenesis.
Within the A-549 lung adenocarcinoma context, disruption of GPD2 impairs the glycerol phosphate shuttle, thereby modifying the balance between glycolytic and oxidative metabolism. This perturbation is particularly relevant for studies of cancer metabolic reprogramming, as it alters electron flux to the electron transport chain, impacting ATP production, ROS signaling, and cellular redox status. The model enables dissection of how mitochondrial glycerol-3-phosphate oxidation influences tumor cell proliferation, survival under nutrient deprivation, and sensitivity to metabolic inhibitors, while also offering insights into broader metabolic disorders such as diabetes, metabolic syndrome, and mitochondrial disease.
Applications include detailed analysis of the glycerol phosphate shuttle in cancer cell metabolism, assessment of mitochondrial respiratory function and ROS biology, and drug toxicity screening using a lung epithelial platform. Experimental assays commonly employed with these polyclonal cells encompass Western blot and RT-qPCR for GPD2 expression, Seahorse-based mitochondrial respiration measurements, DCFDA and other ROS detection methods, glycerol-3-phosphate dehydrogenase activity quantification, metabolomic profiling of glycerol-3-phosphate and DHAP, and functional assays such as viability under metabolic stress and migration/invasion studies. For further details, contact Ascent Research.
